Nitrosamine impurities are compounds that are found during the chemical reactions in the pharmaceutical drug product production. They are formed by the reaction of impurities present in the solvent system and the nitrite ions present in the acidic environment. Nitrosamine impurities contain a nitroso group at the dialkyl-substituted amine group. It is important to screen and check for nitrosamine impurities if the probability of nitrosamine formation is high in the chemical structure. With the presence of nitrosamine impurities it can have adverse effects in the product development process and eventually affect the supply chain.
Pharmaceutical industries are always grappling with the risks involving the nitrosamine presence identification and control of the impurities. Nitrosamine being carcinogenic in nature poses a potential threat to drug development. Monitoring and control is required at every step of the reaction scheme to ensure safe production of the drug product. This can help in understanding the side effects and mitigating them.
Regulatory guidelines and principle for safeguarding the drug product development:
The global regulatory agencies such as USFDA, European medicine agency (EMA) and others are ensuring that the drug product is released with minimal risk of impurities and to prevent the occurrence of nitrosamine at every stage of production. This can enhance the safety and efficacy of the drug molecule.
Nitrosamine impurities guidelines mainly include nitrosamine risk control assessment and control of mutagenic and elemental impurities in the drug compound. The global regulatory agencies have documented and formatted specific impurity control methods to navigate the process, identify and target the nitrosamine impurities and finally to control them. This overall gives a comprehensive guidance to mitigate the nitrosamine impurities in the drug products.
Detailed analysis on the analytical techniques and guidelines:
It is mandatory for the pharmaceutical companies to format a robust approach to effectively control nitrosamine impurities and reduce the potential risks. Therefore periodic documentation is necessary in the respective nitrosamine testing centre to evaluate the potential risks and mitigate them.
The following are the necessary steps undertaken to control the nitrosamine impurities.
1. Risk assessment:
It is to identify the potential sources of nitrosamines and optimization of the manufacturing process for mitigating risks and to check for any possibility of contamination.
2. To exercise control measures, monitor and implementing best practices:
This gives the information on testing of the raw materials and their selection on the basis of quality and potential risk of developing impurity. The process optimization and validation is necessary to ensure if proper measures are taken care of and to minimize the nitrosamine formation. Reliable and reproducible analytical methods should be developed to detect and quantify the nitrosamine impurities in the drug products.
Periodic documentation and review must be conducted to analyse the risk assessment and taking measures and compliance with the regulatory protocols.
3. Regulatory compliance and Audits:
Nitrosamine impurity regulations are to be implemented to ensure compliance and to aid in developing and conducting audits for mitigating the potential risks. Relevant guidelines and practices are to be strategically practiced and to develop robust quality systems and implement them in order to control the nitrosamine risks in drug products.
Other practices can be exercised to evaluate the industrial resources and networks to enhance the nitrosamine detection and control and leveraging the practices through audits and conferences.
